NZ516637A - System for microvolume laser scanning cytometry - Google Patents
System for microvolume laser scanning cytometryInfo
- Publication number
- NZ516637A NZ516637A NZ516637A NZ51663700A NZ516637A NZ 516637 A NZ516637 A NZ 516637A NZ 516637 A NZ516637 A NZ 516637A NZ 51663700 A NZ51663700 A NZ 51663700A NZ 516637 A NZ516637 A NZ 516637A
- Authority
- NZ
- New Zealand
- Prior art keywords
- particles
- sample
- pixel values
- light
- cell
- Prior art date
Links
- 238000004163 cytometry Methods 0.000 title claims description 17
- 239000002245 particle Substances 0.000 claims abstract description 58
- 238000001514 detection method Methods 0.000 claims abstract description 44
- 238000004458 analytical method Methods 0.000 claims abstract description 24
- 230000005284 excitation Effects 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 37
- 238000003556 assay Methods 0.000 claims description 25
- 230000003287 optical effect Effects 0.000 claims description 18
- 230000004044 response Effects 0.000 claims description 14
- 238000004422 calculation algorithm Methods 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 9
- 239000002131 composite material Substances 0.000 claims description 8
- 238000007405 data analysis Methods 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims 11
- 238000005286 illumination Methods 0.000 claims 3
- 239000000090 biomarker Substances 0.000 abstract description 45
- 239000013060 biological fluid Substances 0.000 abstract description 14
- 230000014509 gene expression Effects 0.000 abstract description 3
- 238000004621 scanning probe microscopy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 144
- 239000000523 sample Substances 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 201000010099 disease Diseases 0.000 description 22
- 230000004907 flux Effects 0.000 description 17
- 230000008569 process Effects 0.000 description 16
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 239000011324 bead Substances 0.000 description 8
- 239000003086 colorant Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 6
- 102100038358 Prostate-specific antigen Human genes 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- -1 antibodies Proteins 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108010004469 allophycocyanin Proteins 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000009509 drug development Methods 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 239000002359 drug metabolite Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000010339 dilation Effects 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000012362 drug development process Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000001685 time-resolved fluorescence spectroscopy Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 229910004338 Ti-S Inorganic materials 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000990 laser dye Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1429—Signal processing
- G01N15/1433—Signal processing using image recognition
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F18/00—Pattern recognition
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1484—Optical investigation techniques, e.g. flow cytometry microstructural devices
Landscapes
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Data Mining & Analysis (AREA)
- Multimedia (AREA)
- General Engineering & Computer Science (AREA)
- Evolutionary Biology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Evolutionary Computation (AREA)
- Signal Processing (AREA)
- Artificial Intelligence (AREA)
- Dispersion Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14479899P | 1999-07-21 | 1999-07-21 | |
| PCT/US2000/011133 WO2001008081A1 (en) | 1999-07-21 | 2000-04-26 | System for microvolume laser scanning cytometry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ516637A true NZ516637A (en) | 2003-08-29 |
Family
ID=22510184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ516637A NZ516637A (en) | 1999-07-21 | 2000-04-26 | System for microvolume laser scanning cytometry |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1203339A4 (ja) |
| JP (1) | JP2003505707A (ja) |
| KR (1) | KR20020013970A (ja) |
| AU (1) | AU4491100A (ja) |
| CA (1) | CA2379836A1 (ja) |
| MX (1) | MXPA01013398A (ja) |
| NZ (1) | NZ516637A (ja) |
| WO (1) | WO2001008081A1 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8497131B2 (en) | 1999-10-06 | 2013-07-30 | Becton, Dickinson And Company | Surface enhanced spectroscopy-active composite nanoparticles comprising Raman-active reporter molecules |
| US7192778B2 (en) | 1999-10-06 | 2007-03-20 | Natan Michael J | Surface enhanced spectroscopy-active composite nanoparticles |
| WO2002025280A1 (en) | 2000-09-20 | 2002-03-28 | Surromed, Inc. | Method for monitoring resting and activated platelets in unfixed blood samples |
| US6861263B2 (en) | 2001-01-26 | 2005-03-01 | Surromed, Inc. | Surface-enhanced spectroscopy-active sandwich nanoparticles |
| US7572642B2 (en) | 2001-04-18 | 2009-08-11 | Ambrigen, Llc | Assay based on particles, which specifically bind with targets in spatially distributed characteristic patterns |
| DE10291983D2 (de) * | 2001-05-07 | 2004-04-15 | Deutsches Krebsforsch | Fluoreszenzfluktuationsmikroskop, -messmodul bzw.-scanmodul und Verfahren zur Fluoreszenzfluktuationsmessung sowie Verfahren und Vorrichtung zur Justage eines Fluoreszenzfluktuationsmikroskops |
| JP2008545959A (ja) * | 2005-05-25 | 2008-12-18 | スティフテルセン ウニヴェルジテーツフォルスクニング ベルゲン | 顕微鏡装置および薬品、物理療法と生物学的危険物質のためのふるい分け（ｓｃｒｅｅｎｉｎｇ）方法 |
| US8409863B2 (en) | 2005-12-14 | 2013-04-02 | Becton, Dickinson And Company | Nanoparticulate chemical sensors using SERS |
| US7796251B2 (en) * | 2006-03-22 | 2010-09-14 | Itt Manufacturing Enterprises, Inc. | Method, apparatus and system for rapid and sensitive standoff detection of surface contaminants |
| JP4909254B2 (ja) * | 2007-12-26 | 2012-04-04 | 日本電信電話株式会社 | 浮遊粒子状物質測定装置 |
| CN102414550B (zh) * | 2009-04-27 | 2014-07-16 | Ei频谱有限责任公司 | 移液器仪器 |
| DK3206010T3 (da) * | 2012-05-30 | 2024-04-08 | Iris Int Inc | Strømningscytometer |
| US9746412B2 (en) | 2012-05-30 | 2017-08-29 | Iris International, Inc. | Flow cytometer |
| CN113302492A (zh) * | 2019-01-03 | 2021-08-24 | 彼克斯赛尔医疗科技有限公司 | 用于分析流体样品的***和方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE455646B (sv) * | 1984-10-22 | 1988-07-25 | Radians Innova Ab | Fluorescensanordning |
| US5107422A (en) * | 1989-10-02 | 1992-04-21 | Kamentsky Louis A | Method and apparatus for measuring multiple optical properties of biological specimens |
| US5127730A (en) * | 1990-08-10 | 1992-07-07 | Regents Of The University Of Minnesota | Multi-color laser scanning confocal imaging system |
| JPH0599912A (ja) * | 1991-10-11 | 1993-04-23 | Union Shokai:Kk | アナログフイルター装置 |
| WO1993016442A1 (en) * | 1992-02-18 | 1993-08-19 | Neopath, Inc. | Method for identifying objects using data processing techniques |
| US5377003A (en) * | 1992-03-06 | 1994-12-27 | The United States Of America As Represented By The Department Of Health And Human Services | Spectroscopic imaging device employing imaging quality spectral filters |
| US5889881A (en) * | 1992-10-14 | 1999-03-30 | Oncometrics Imaging Corp. | Method and apparatus for automatically detecting malignancy-associated changes |
| US5556764A (en) * | 1993-02-17 | 1996-09-17 | Biometric Imaging, Inc. | Method and apparatus for cell counting and cell classification |
| US5456252A (en) * | 1993-09-30 | 1995-10-10 | Cedars-Sinai Medical Center | Induced fluorescence spectroscopy blood perfusion and pH monitor and method |
| JP3474612B2 (ja) * | 1993-12-03 | 2003-12-08 | 浜松ホトニクス株式会社 | 光検出装置 |
| JPH08313348A (ja) * | 1995-05-16 | 1996-11-29 | Kanagawa Kagaku Gijutsu Akad | 赤外光時間応答測定装置 |
| US5582705A (en) * | 1995-05-19 | 1996-12-10 | Iowa State University Research Foundation, Inc. | Multiplexed capillary electrophoresis system |
-
2000
- 2000-04-26 WO PCT/US2000/011133 patent/WO2001008081A1/en active IP Right Grant
- 2000-04-26 MX MXPA01013398A patent/MXPA01013398A/es unknown
- 2000-04-26 KR KR1020027000806A patent/KR20020013970A/ko not_active Application Discontinuation
- 2000-04-26 EP EP00926370A patent/EP1203339A4/en not_active Withdrawn
- 2000-04-26 NZ NZ516637A patent/NZ516637A/en unknown
- 2000-04-26 CA CA002379836A patent/CA2379836A1/en not_active Abandoned
- 2000-04-26 JP JP2001513096A patent/JP2003505707A/ja active Pending
- 2000-04-26 AU AU44911/00A patent/AU4491100A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2379836A1 (en) | 2001-02-01 |
| JP2003505707A (ja) | 2003-02-12 |
| EP1203339A4 (en) | 2006-09-13 |
| WO2001008081A1 (en) | 2001-02-01 |
| KR20020013970A (ko) | 2002-02-21 |
| EP1203339A1 (en) | 2002-05-08 |
| AU4491100A (en) | 2001-02-13 |
| MXPA01013398A (es) | 2003-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7336812B2 (en) | System for microvolume laser scanning cytometry | |
| JP4215397B2 (ja) | 多重分析物診断システム | |
| US8660332B2 (en) | Blood and cell analysis using an imaging flow cytometer | |
| US6350613B1 (en) | Determination of white blood cell differential and reticulocyte counts | |
| JP2019109249A (ja) | 生物学的状態を検出するシステムおよび方法 | |
| US20090003681A1 (en) | Blood and cell analysis using an imaging flow cytometer | |
| US20030096324A1 (en) | Methods for differential cell counts including related apparatus and software for performing same | |
| NZ516637A (en) | System for microvolume laser scanning cytometry | |
| JP2005502872A (ja) | 光バイオディスクシステムを使用した、核の形態に基づく白血球の型の識別および定量 | |
| KR20080034012A (ko) | 마이크로입자를 분류하는 방법과 데이터 구조 및 시스템 | |
| Bachar et al. | An artificial intelligence‐assisted diagnostic platform for rapid near‐patient hematology | |
| US20230332999A1 (en) | Specimen analysis system and specimen analysis method | |
| CN112161913A (zh) | 一种用于流式荧光分析***的分析方法及设备 | |
| US20230296591A1 (en) | Sample analysis method, sample analyzer, and computer-readable storage medium | |
| US8349256B2 (en) | Blood cell analyzer, blood cell analyzing method, and computer program product | |
| Pierzchalski et al. | Introduction A: Recent advances in cytometry instrumentation, probes, and methods | |
| US11592367B2 (en) | Method for analyzing and selecting a specific droplet among a plurality of droplets and associated apparatus | |
| Norton et al. | Cell enumeration and characterization in microvolume laser scanning cytometry: a multicolor image-processing package | |
| US20240029458A1 (en) | A method for automated determination of platelet count based on microscopic images of peripheral blood smears | |
| Leary | Cytometry of Single-Cells for Biology and Biomedicine | |
| Tárnok et al. | Immunophenotyping using a laser scanning cytometer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |